Search Results - "Lux, M.P."

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients by Harbeck, N, Schmitt, M, Meisner, C, Friedel, C, Untch, M, Schmidt, M, Sweep, C.G.J, Lisboa, B.W, Lux, M.P, Beck, T, Hasmüller, S, Kiechle, M, Jänicke, F, Thomssen, C

“…Abstract Aim Final 10-year analysis of the prospective randomised Chemo-N0 trial is presented. Based on the Chemo-N0 interim results and an European…”
Get full text

Scenarios of cost-savings associated with Oncotype DX® test-guided decisions for adjuvant chemotherapy in early breast cancer in Germany by Lux, M.P., Brandt, L., Herrmann, K.H., Ecker, T.

Get full text

Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients by Hack, C.C., Häberle, L., Brucker, S.Y., Janni, W., Volz, B., Loehberg, C.R., Hartkopf, A.D., Walter, C.-B., Baake, G., Fridman, A., Malter, W., Wuerstlein, R., Harbeck, N., Hoffmann, O., Kuemmel, S., Martin, B., Thomssen, C., Graf, H., Wolf, C., Lux, M.P., Bayer, C.M., Rauh, C., Almstedt, K., Gass, P., Heindl, F., Brodkorb, T., Willer, L., Lindner, C., Kolberg, H.-C., Krabisch, P., Weigel, M., Steinfeld-Birg, D., Kohls, A., Brucker, C., Schulz, V., Fischer, G., Pelzer, V., Rack, B., Beckmann, M.W., Fehm, T., Rody, A., Maass, N., Hein, A., Fasching, P.A., Nabieva, N.

“…Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine…”
Get full text

Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany by Lux, M.P., Minartz, C., Müller-Huesmann, H., Sandor, M.F., Herrmann, K.H., Radeck-Knorre, S., Neubauer, A.S.

“…•Gene expression tests have a high impact on the total value of breast cancer treatment.•Oncotype DX test can help to avoid unnecessary chemotherapy and…”
Get full text

Factors correlating with reexcision after breast-conserving therapy by Bani, M.R, Lux, M.P, Heusinger, K, Wenkel, E, Magener, A, Schulz-Wendtland, R, Beckmann, M.W, Fasching, P.A

“…Abstract Aim The aim of this study was to evaluate factors affecting the risk for reexcision following breast-conserving surgery. Positive tumor margins are…”
Get full text

Patients' attitudes to totally implantable venous access port systems for gynecological or breast malignancies by Kreis, H, Loehberg, C.R, Lux, M.P, Ackermann, S, Lang, W, Beckmann, M.W, Fasching, P.A

“…Abstract Aims The aim of this study was to analyze patients’ port-related quality of life. Patients and methods 260 consecutive patients with gynecological or…”
Get full text

Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients by Meier-Meitinger, M, Rauh, C, Adamietz, B, Fasching, P.A, Schwab, S.A, Haeberle, L, Hein, A, Bayer, C.M, Bani, M.R, Lux, M.P, Hartmann, A, Wachter, D.L, Uder, M, Schulz-Wendtland, R, Beckmann, M.W, Heusinger, K

“…Abstract Background Re-operations after breast conserving surgery (BCS) are necessary, when specimen margins are not free of breast cancer cells. This study…”
Get full text

Risk and risk assessment for breast cancer: Molecular and clinical aspects by Beckmann, M.W, Bani, M.R, Fasching, P.A, Strick, R, Lux, M.P

“…Abstract Chemoprevention, prophylactic surgery and intensified screening programs are options which can be offered the patients with an increased lifetime risk…”
Get full text

Entwicklungen der gynäkologischen Onkologie – Verbesserung der Versorgung auf vielen Ebenen by Beckmann, M.W., Lux, M.P., Fasching, P.A., Scharl, A.

“…Zusammenfassung Die Zahl der Krebserkrankungen steigt weltweit kontinuierlich an. In Deutschland sind im Jahr 2010 224.910 Krebserkrankungen und 100.403…”
Get full text

292P - BRCA1/2 testing in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study by Lux, M.P., Lewis, K., Rider, A., Niyazov, A.

“…Mutations in breast cancer susceptibility gene 1 or 2 (BRCA1/2) are risk factors for developing cancer, especially for breast cancer (BC) and ovarian cancer…”
Get full text

BRCA1/2 testing in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study by Lux, M.P., Lewis, K., Rider, A., Niyazov, A.

Get full text

PCN98 Scenarios of Cost-Savings Associated with Oncotype DX® Test - Guided Decisions for Adjuvant Chemotherapy in EARLY Breast Cancer in Germany by Lux, M.P., Brandt, L., Herrmann, K., Ecker, T.

Get full text

P038 - Scenarios of cost-savings associated with Oncotype DX® test-guided decisions for adjuvant chemotherapy in early breast cancer in Germany by Lux, M.P., Brandt, L., Herrmann, K.H., Ecker, T.

Get full text

317P Awareness of genomic testing among patients with breast cancer in Europe by Cardone, A., Bell, D., Biurrun, C.B., Cardoso, F., Csaba, L.D., Guéroult-Accolas, L., Lux, M.P., Piris, A. Ramírez, Rubio, I., Simcock, R., D’Antona Fidanzia, R.

Get full text

312P Real-world (RW) multi-country study of BRCA1/2 mutation (BRCA1/2mut) testing trends among adult patients (pts) with HER2− advanced breast cancer (ABC) by Mahtani, R., Niyazov, A., Lewis, K., Massey, L., Rider, A., Arondekar, B., Lux, M.P.

Get full text

313P Real-world multi-country study of treatment trends among patients (pts) with HER2− BRCA1/2 mutated (BRCA1/2mut) advanced breast cancer (ABC) by Mahtani, R., Niyazov, A., Lewis, K., Massey, L., Rider, A., Arondekar, B., Lux, M.P.

Get full text

314P Real-world (RW) multi-country study of BRCA1/2 testing in adult patients (pts) with HER2−advanced breast cancer (ABC) by Lux, M.P., Niyazov, A., Lewis, K., Rider, A., Arondekar, B., Mahtani, R.

Get full text

1126P Budget impact of Oncotype DX test compared to further gene expression tests in patients with early breast cancer in Germany by Lux, M.P., Minartz, C., Müller-Huesmann, H., Sandor, M-F., Herrmann, K.H., Radeck-Knorre, S., Neubauer, A.S.

Get full text

166P Awareness and availability of routine germline BRCA1/2 (gBRCA1/2) mutation testing in patients (pts) with advanced breast cancer (ABC) in Germany by Lux, M.P., Decker, T., Runkel, E.D., Niyazov, A., Quek, R.G.W., Glastetter, E., Marschner, N.W., Harbeck, N.

Get full text

157P Germline BRCA1/2 (gBRCA1/2) testing patterns among oncologists (ONC) treating HER2- advanced breast cancer (ABC): Results from a multi-country real-world study by Mahtani, R., Niyazov, A., Lewis, K., Wild, R., Rider, A., Arondekar, B., Lux, M.P.

Get full text